GlassScriptPhysician profile
Lindsey Phyfer
NPI 1902538895
$2,630.72
in general payments reported to CMS, 2019-2025
33 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $822 · 2023: $1,024 · 2024: $442 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.19 | 2023-2025 | |
| Seagen INC. | $294.02 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Astrazeneca Pharmaceuticals LP | $248.04 | 2021-2024 | Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $203.03 | 2022-2024 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $145.23 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $141.97 | 2022-2023 | Imbruvica, Epkinly |
| Novartis Pharmaceuticals Corporation | $117.66 | 2023-2024 | |
| Celgene Corporation | $97.39 | 2022-2023 | Reblozyl, Opdualag |
| Eisai INC. | $90.57 | 2022 | |
| Exelixis INC. | $78.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.65 | 2023 | Iclusig |
| Regeneron Healthcare Solutions, INC. | $59.31 | 2022-2023 | Libtayo |
| Janssen Biotech, INC. | $55.95 | 2022-2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $53.97 | 2022-2023 | Opdualag |
| Daiichi Sankyo INC. | $51.66 | 2022-2024 | Enhertu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $49.99 | 2022-2024 | |
| Amgen INC. | $46.44 | 2023 | Kyprolis, Blincyto |
| Incyte Corporation | $46.25 | 2022-2023 | Jakafi, Pemazyre |
| Genentech USA, INC. | $45.22 | 2023 | Venclexta, Tecentriq |
| Lilly USA, LLC | $42.15 | 2022-2023 | Verzenio, Jaypirca, Retevmo |
| Tersera Therapeutics LLC | $35.30 | 2022 | |
| Pfizer INC. | $34.95 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.13 | 2023 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $32.69 | 2022-2023 | Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $29.46 | 2022 | |
| Genmab U.S., INC. | $25.64 | 2023 | Epkinly |
| Pharmacosmos Therapeutics INC. | $23.76 | 2022 | |
| Gilead Sciences, INC. | $23.48 | 2023 | |
| Alexion Pharmaceuticals, INC. | $20.80 | 2023 | Ultomiris |
| Genzyme Corporation | $20.39 | 2023 | |
| Blueprint Medicines Corporation | $15.10 | 2022 | |
| Aveo Pharmaceuticals, INC. | $15.03 | 2022 | |
| Beigene USA, INC. | $14.83 | 2023 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Phyfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.